Prevention of severe RSV disease in babies
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. We offer an antibody developed against the RS virus called nirsevimab in our hospitals to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV.
Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab will be offered to:
- All babies born after 1 August 2024, at maternity and child health clinics: During the routine check-up, we'll discuss the family’s interest in the RSV preventive antibody. If they choose to proceed, it will be administered during the next routine check-up—no need to book a separate appointment.
- Newborns in all HUS maternity hospitals starting 23 October 2024: Nirsevimab will be provided during the discharge examination before you take your baby home.
- Infants under one year old in high-risk groups for RSV infection, starting 4 November 2024, at HUS: Appointments can be booked from 28 October 2024 onwards. If your child already has a scheduled visit to HUS, nirsevimab can be administered during that appointment.
For more information on preventing RSV in babies, please visit the HUS website(external link).
- Family centre